Inhibitors of Receptor for Advanced Glycation-End products (RAGE) for treatment of liver cancer

The receptor for advanced glycation-end prod-ucts (RAGE) has been shown to play a central role not only in acute or chronic inflammatory diseases but also in septic shock, late diabetes and cancer. Here we provide a new application of RAGE inhibition in the field of cancer prevention and treatment.

Further Information: PDF

DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955

Contact
Dr. Ruth Herzog

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Future AR/VR controllers could be the palm of your hand

Carnegie Mellon University’s EgoTouch creates simple interfaces for virtual and augmented reality. The new generation of augmented and virtual reality controllers may not just fit in the palm of your…

‘Game changer’ in lithium extraction

Rice researchers develop novel electrochemical reactor. A team of Rice University researchers led by Lisa Biswal and Haotian Wang has developed an innovative electrochemical reactor to extract lithium from natural…

The blue-green sustainable proteins of seaweed

… may soon be on your plate. The protein in sea lettuce, a type of seaweed, is a promising complement to both meat and other current alternative protein sources. Seaweed…